Brainsway Ltd. (BWAY)
NASDAQ: BWAY · IEX Real-Time Price · USD
5.03
+0.20 (4.22%)
Jul 1, 2022 10:07 AM EDT - Market open
Company Description
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally.
It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Brainsway Ltd.
| Country | United States |
| Founded | 2003 |
| IPO Date | Apr 17, 2019 |
| Industry | Health Care Equipment & Supplies |
| Sector | Health Care |
| Employees | 118 |
Contact Details
Address:
Bynet Building Jerusalem 9777518 Israel | |
| Phone | 972 2 582 4030 |
Stock Details
| Ticker Symbol | BWAY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $11.00 |
| CIK Code | 0001076643 |
| CUSIP Number | 10501L106 |
| ISIN Number | US10501L1061 |
| Employer ID | 04-3285165 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher R. von Jako Ph.D. | President and Chief Executive Officer |
| Richard Scott Areglado | Senior Vice President and Chief Financial Officer |
| Hadar Levy | Senior Vice President and Chief Operating Officer |
| Christopher J. Boyer Ph.D. | Vice President of Global Marketing |
| Avner Hagai | Founder and Independent Vice-Chairman |
| Prof. Abraham Zangen | Co-Founder, Member of Scientific Advisory Board and Director |
| Dr. Yiftach Roth Ph.D. | Chief Scientist |
| Menachem C. Klein Esq. | Vice President, General Counsel and Corporate Secretary |
| Dr. Joachim Seidel Ph.D. | Vice President of Corporate Development and Strategy |
| Dr. Aron Tendler | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 12, 2013 | REVOKED | Commission order revoking Exchange Act registration [Section 12(j)] |
| Sep 10, 2001 | 4 | Statement of changes in beneficial ownership of securities |
| Sep 5, 2001 | 8-K | Current report |
| Sep 5, 2001 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Sep 5, 2001 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Aug 15, 2001 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 8, 2001 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Aug 8, 2001 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 5, 2001 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Jun 27, 2001 | 8-K | Current report |